Claims for Patent: 6,217,866

Summary for Patent: 6,217,866

Title:	Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
Abstract:	Hybridoma cell lines producing monoclonal antibodies specific to the human epidermal growth factor receptor are disclosed. The antibodies are capable of inhibiting the growth of human tumor cells expressing human epidermal growth factor receptors. Therapeutic uses of these monoclonal antibodies by themselves and in combination with anti-neoplastic agents are also disclosed.
Inventor(s):	Schlessinger; Joseph (New York, NY), Givol; David (Rehovot, IL), Bellot; Francoise (Fresnes, FR), Kris; Richard (Tucson, AZ), Ricca; George A. (Blue Bell, PA), Cheadle; Christopher (West Chester, PA), South; Victoria J. (Audubon, PA)
Assignee:	Rhone-Poulenc Rorer International (Holdings), Inc. (Greenville, DE)
Application Number:	08/487,761
Patent Claims:	1. A method for inhibiting the growth of human tumor cells that express human EGF receptors and are mitogenically stimulated by EGF, the method comprising administering an effective amount of an anti-neoplastic agent and an effective amount of a monoclonal antibody to a human cancer patient having said tumor cells; (i) wherein said antibody binds to the extra-cellular domain of the human EGF receptor of said tumor cell; (ii) wherein the antibody is not conjugated to the anti-neoplastic agent; and (iii) wherein the antibody inhibit the binding of EGF to the EGF receptor. 2. A method for inhibiting the growth of human tumor cells that express human EGF receptors and are mitogenically stimulated by human EGF according to claim 1 wherein said anti-neoplastic agent is doxorubicin. 3. A method for inhibiting the growth of human tumor cells that express human EGF receptors and are mitogenically stimulated by human EGF according to claim 1 wherein said anti-neoplastic agent is cisplatin. 4. A method for inhibiting the growth of human tumor cells that express human EGF receptors and are mitogenically stimulated by human EGF according to claim 1 wherein said monoclonal antibody is 108 produced by hybridoma cell line ATCC HB 9764. 5. A method for inhibiting the growth of human tumor cells that express EGF receptors and are mitogenically stimulated by human EGF according to claim 1 wherein said monoclonal antibody is further characterized by its capability to inhibit the growth of human oral epidermoid carcinoma (KB) cells by binding to the extra-cellular domain of the human EGF receptor of said KB cells in an antigen-antibody complex. 6. A therapeutic composition comprising an amount of monoclonal antibody and an anti-neoplastic agent effective to inhibit the growth of human tumor cells that express human EGF receptors and are mitogenically stimulated by human EGF in association with a pharmaceutical carrier; (i) wherein the antibody binds to the extracellular domain of the human EGF receptor of the tumor cells; (ii) wherein the antibody is not conjugated to the anti-neoplastic agent; and (iii) wherein the antibody inhibits the binding of EGF to the EGF receptor. 7. A therapeutic composition according to claim 6 wherein said anti-neoplastic agent is doxorubicin. 8. A therapeutic composition according to claim 6 wherein said anti-neoplastic agent is cisplatin. 9. A therapeutic composition according to claim 6 wherein said monoclonal antibody is 108 produced by hybridoma cell line ATCC HB 9764.

Details for Patent 6,217,866

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2018-04-17
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2018-04-17

International Patent Family for US Patent 6,217,866

Country	Patent Number	Estimated Expiration
Austria	123070
Austria	214943
Australia	4128089
Canada	1340417
Germany	122004000040